M2I Vision : Build in France a world-class industrial partner for custom synthesis and formulation of niche products in Healthcare (mainly generics), veterinary art, biological crop protection and organic electronics (Re)design synthetic routes and industrial processes for « hard to make » molecules (core capability) Propose to our clients a one stop shop from specification to regulatory clearance (DMF, MA) by teaming up with R&D and marketing teams The company operates a R&D center rance and a cGMP manufacturing plant. M2I holds a portfolio of proprietary DMFs and has already successfully applied its nonconventional retrosynthetic approach of active ingredients, using continuus processing, to solve important quality and stability issues on proprietary APIs. M2I also develops pheromones based solutions for crop protection and veterinary art. M2I works in close partnership with its clients to develop and supply high quality molecules in a cost efficient way.
Looking for a particular M2I Life Sciences employee's phone or email?
The M2I Life Sciences annual revenue was $9.4 million in 2026.
Jerome Aubert is the CFO of M2I Life Sciences.
3 people are employed at M2I Life Sciences.
M2I Life Sciences is based in Saint-Cloud, Ile-de-France.
The NAICS codes for M2I Life Sciences are [54, 541, 541713, 5417, 54171].
The SIC codes for M2I Life Sciences are [87, 873].